TY - JOUR
T1 - Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer
AU - Tokunaga, Eriko
AU - Okada, Satoko
AU - Kitao, Hiroyuki
AU - Shiotani, Satoko
AU - Saeki, Hiroshi
AU - Endo, Kazuya
AU - Morita, Masaru
AU - Kakeji, Yoshihiro
AU - Maehara, Yoshihiko
N1 - Funding Information:
Acknowledgments We are grateful to Ms T. Shishino and Ms K. Yamashita for their valuable technical assistance. This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
PY - 2011/4
Y1 - 2011/4
N2 - Purpose: The link between BRCA1 dysfunction and basal-like breast cancer or triple-negative breast cancer (TNBC) has been suggested; however, the associations of other factors involved in the Fanconi anemia (FA)/BRCA pathway with the pathogenesis of basal-like breast cancer remain unidentified. FANCF protein is a component of the FA core complex. The methylation of CpG islands in the FANCF gene plays an important role in occurrence of ovarian cancer and also is an important regulator of cisplatin sensitivity of ovarian cancer. The purpose of this study is to investigate the frequency of FANCF methylation, and to discuss its involvement in the pathogenesis of TNBC and its potency as a predictor of cisplatin sensitivity for breast cancer. Methods: The methylation of the FANCF gene promoter was investigated, using methylation-specific PCR, in genomic DNA of 99 invasive breast carcinoma specimens obtained from Japanese patients. Results: FANCF methylation was recognized in only 4 of 99 cases (4.0%). No significant correlation was found between FANCF methylation and the expression of ER, PR, HER2, and TNBC. Conclusions: FANCF methylation is a rare event in Japanese primary invasive breast cancer. This suggests it is not involved in the pathogenesis of TNBC, and it could not be used as a predictor of cisplatin sensitivity in breast cancer.
AB - Purpose: The link between BRCA1 dysfunction and basal-like breast cancer or triple-negative breast cancer (TNBC) has been suggested; however, the associations of other factors involved in the Fanconi anemia (FA)/BRCA pathway with the pathogenesis of basal-like breast cancer remain unidentified. FANCF protein is a component of the FA core complex. The methylation of CpG islands in the FANCF gene plays an important role in occurrence of ovarian cancer and also is an important regulator of cisplatin sensitivity of ovarian cancer. The purpose of this study is to investigate the frequency of FANCF methylation, and to discuss its involvement in the pathogenesis of TNBC and its potency as a predictor of cisplatin sensitivity for breast cancer. Methods: The methylation of the FANCF gene promoter was investigated, using methylation-specific PCR, in genomic DNA of 99 invasive breast carcinoma specimens obtained from Japanese patients. Results: FANCF methylation was recognized in only 4 of 99 cases (4.0%). No significant correlation was found between FANCF methylation and the expression of ER, PR, HER2, and TNBC. Conclusions: FANCF methylation is a rare event in Japanese primary invasive breast cancer. This suggests it is not involved in the pathogenesis of TNBC, and it could not be used as a predictor of cisplatin sensitivity in breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=79956372634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79956372634&partnerID=8YFLogxK
U2 - 10.1007/s12282-009-0175-z
DO - 10.1007/s12282-009-0175-z
M3 - Article
C2 - 19813073
AN - SCOPUS:79956372634
SN - 1340-6868
VL - 18
SP - 120
EP - 123
JO - Breast Cancer
JF - Breast Cancer
IS - 2
ER -
